Benzylpenicilloyl polylysine

  • Biologic
  • PRE-PEN

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Benzylpenicilloyl polylysine: storage and handling

Refrigerate
Yes, as the label states
Label statement
Store PRE-PEN refrigerated at 2°C to 8°C (36°F to 46°F).
Freezing
Not addressed
Room temperature
up to 1 day at or below 25°C (77°F)
Label statement
If removed from refrigerator, PRE-PEN should be kept at room temperature up to 25°C (77°F) and must be used within 24 hours.
Back into the refrigerator
Not addressed
Light
Not addressed
Shaking
Not addressed

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

Within the label's stated room-temperature allowance (up to 1 day at up to 25°C (77°F)). Follow the label's instructions for what to do next.

Entered: 1 day at up to 77°F (25°C).

If removed from refrigerator, PRE-PEN should be kept at room temperature up to 25°C (77°F) and must be used within 24 hours.
Discard any unused portion.

If anything else happened to the product, or you are unsure, Contact the manufacturer about this product; the label text ClinDose has does not print a phone number for it.

All storage statements on the label (3)
  • Discard any unused portion.
  • Store PRE-PEN refrigerated at 2°C to 8°C (36°F to 46°F).
  • If removed from refrigerator, PRE-PEN should be kept at room temperature up to 25°C (77°F) and must be used within 24 hours.

FDA label version 5, effective January 12, 2024. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

No Part D formulary in the CMS files (2026Q3) lists this drug. It may be covered under Part B or not covered.

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.